Bimekizumab (dual 17A/17F inhibitor) RCT in AS. ASAS40 45% vs 23% at week 16. All secondary clinical and imaging endpoints also + @RheumNow #EULAR2022 OP0019 https://t.co/RiZ7Divap3 https://t.co/ushogL5TaX
Links:
EULAR Abstract Archive
http://scientific.sparx-ip.net/archiveeular/index.cfm?c=a&searchfor=op0019&view…
01-06-2022